<?xml version='1.0' encoding='utf-8'?>
<document id="29379439"><sentence text="S-Ketamine Mediates Its Acute and Sustained Antidepressant-Like Activity through a 5-HT1B Receptor Dependent Mechanism in a Genetic Rat Model of Depression."><entity charOffset="0-10" id="DDI-PubMed.29379439.s1.e0" text="S-Ketamine" /></sentence><sentence text="Rationale: The mechanisms responsible for the unique antidepressant properties of ketamine have only been partly resolved"><entity charOffset="82-90" id="DDI-PubMed.29379439.s2.e0" text="ketamine" /></sentence><sentence text=" Recent preclinical reports implicate the neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] in the antidepressant-like response of ketamine, and modulation of 5-HT1B receptors has been hypothesized to attain an important role"><entity charOffset="59-68" id="DDI-PubMed.29379439.s3.e0" text="serotonin" /><entity charOffset="91-95" id="DDI-PubMed.29379439.s3.e1" text="5-HT" /><entity charOffset="137-145" id="DDI-PubMed.29379439.s3.e2" text="ketamine" /><entity charOffset="165-172" id="DDI-PubMed.29379439.s3.e3" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e0" e2="DDI-PubMed.29379439.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e0" e2="DDI-PubMed.29379439.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e0" e2="DDI-PubMed.29379439.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e0" e2="DDI-PubMed.29379439.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e1" e2="DDI-PubMed.29379439.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e1" e2="DDI-PubMed.29379439.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e1" e2="DDI-PubMed.29379439.s3.e3" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e2" e2="DDI-PubMed.29379439.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29379439.s3.e2" e2="DDI-PubMed.29379439.s3.e3" /></sentence><sentence text=" Objectives: To evaluate the role of endogenous stimulation of 5-HT1B heteroreceptors in the antidepressant-like activity of S-ketamine"><entity charOffset="125-135" id="DDI-PubMed.29379439.s4.e0" text="S-ketamine" /><entity charOffset="63-72" id="DDI-PubMed.29379439.s4.e1" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.29379439.s4.e1" e2="DDI-PubMed.29379439.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29379439.s4.e1" e2="DDI-PubMed.29379439.s4.e0" /></sentence><sentence text=" Method: Flinders sensitive line (FSL) rats, a genetic model of depression, were depleted of endogenous 5-HT by 4-chloro-DL-phenylalanine methyl ester HCl administration (pCPA; 86 mg/kg/day for 3 days)"><entity charOffset="104-108" id="DDI-PubMed.29379439.s5.e0" text="5-HT" /><entity charOffset="112-154" id="DDI-PubMed.29379439.s5.e1" text="4-chloro-DL-phenylalanine methyl ester HCl" /><pair ddi="false" e1="DDI-PubMed.29379439.s5.e0" e2="DDI-PubMed.29379439.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29379439.s5.e0" e2="DDI-PubMed.29379439.s5.e1" /></sentence><sentence text=" In pCPA-pretreated and control FSL rats, the acute and sustained effects of a single dose of S-ketamine (15 mg/kg) and the selective 5-HT1B receptor agonist CP94253 (1-6 mg/kg) alone and in combination with S-ketamine were studied in the forced swim test (FST), a commonly used assay that detects antidepressant activity"><entity charOffset="94-104" id="DDI-PubMed.29379439.s6.e0" text="S-ketamine" /><entity charOffset="208-218" id="DDI-PubMed.29379439.s6.e1" text="S-ketamine" /><entity charOffset="134-143" id="DDI-PubMed.29379439.s6.e2" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.29379439.s6.e0" e2="DDI-PubMed.29379439.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29379439.s6.e0" e2="DDI-PubMed.29379439.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29379439.s6.e0" e2="DDI-PubMed.29379439.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29379439.s6.e2" e2="DDI-PubMed.29379439.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29379439.s6.e2" e2="DDI-PubMed.29379439.s6.e1" /></sentence><sentence text=" Results: pCPA pretreatment decreased cortical 5-HT levels to âˆ¼6% but did not affect the baseline behavioral phenotype of FSL rats"><entity charOffset="47-51" id="DDI-PubMed.29379439.s7.e0" text="5-HT" /></sentence><sentence text=" S-ketamine demonstrated acute and sustained antidepressant-like activity, both of which were abolished by 5-HT depletion"><entity charOffset="1-11" id="DDI-PubMed.29379439.s8.e0" text="S-ketamine" /><entity charOffset="107-111" id="DDI-PubMed.29379439.s8.e1" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.29379439.s8.e0" e2="DDI-PubMed.29379439.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29379439.s8.e0" e2="DDI-PubMed.29379439.s8.e1" /></sentence><sentence text=" Combining S-ketamine with a sub-effective dose of CP94253 (1 mg/kg) rescued S-ketamine's acute and sustained antidepressant-like effects, when CP94253 was administered 2 h prior to the FST"><entity charOffset="11-21" id="DDI-PubMed.29379439.s9.e0" text="S-ketamine" /></sentence><sentence text=" Co-administration of S-ketamine and CP94253 did not affect the plasma level of either compound, suggesting that the observed behavioral interaction could not be ascribed to a kinetic drug-drug interaction"><entity charOffset="22-32" id="DDI-PubMed.29379439.s10.e0" text="S-ketamine" /></sentence><sentence text=" Conclusion: 5-HT1B receptor activation during testing appears to be critical for S-ketamine's antidepressant-like potentials in this model"><entity charOffset="13-22" id="DDI-PubMed.29379439.s11.e0" text="5-HT" /></sentence><sentence text="" /></document>